Ohsu Knight Cancer Institute

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Employees: -

Market Cap: -

Website: http://www.ohsu.edu/knight-cancer-institute

Clinical Trials

Research Study in Healthy Volunteers of Patients With Fanconi Anemia, Myeloproliferative Disorders, or Myeloma

Completed

Conditions: Chronic Myeloproliferative Disorders
Fanconi Anemia
Multiple Myeloma and Plasma Cell Neoplasm
Myelodysplastic/Myeloproliferative Neoplasms

First Posted Date: 2009-05-12

Last Posted Date: 2022-07-05

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 213

Registration Number: NCT00900055

Locations: 🇺🇸
Knight Cancer Institute at Oregon Health and Science University, Portland, Oregon, United States

Evaluating Cell Damage in Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, or Fanconi Anemia; in Patients Who Were Exposed to Alkylating Agents; and in Healthy Volunteers

Completed

Conditions: Leukemia
Myelodysplastic Syndromes

First Posted Date: 2009-05-12

Last Posted Date: 2017-12-04

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 35

Registration Number: NCT00899795

Locations: 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

Broccoli Sprout Extract in Treating Women Who Have Had a Mammogram and Breast Biopsy

Phase 2

Completed

Conditions: Precancerous Condition
Breast Cancer

Interventions: Other: placebo
Dietary Supplement: broccoli sprout extract

First Posted Date: 2009-02-13

Last Posted Date: 2017-04-27

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 54

Registration Number: NCT00843167

Locations: 🇺🇸
Knight Cancer Institute at Oregon Health and Science University, Portland, Oregon, United States

Sorafenib, Epirubicin, Ifosfamide, and Radiation Therapy Followed By Surgery in Treating Patients With High-Risk Stage II or Stage III Soft Tissue Sarcoma

Phase 1

Completed

Conditions: Sarcoma

Interventions: Drug: epirubicin hydrochloride
Drug: ifosfamide
Drug: sorafenib tosylate
Other: immunoenzyme technique
Other: immunohistochemistry staining method
Other: laboratory biomarker analysis
Procedure: adjuvant therapy
Procedure: neoadjuvant therapy
Procedure: therapeutic conventional surgery
Radiation: hypofractionated radiation therapy

First Posted Date: 2009-01-15

Last Posted Date: 2018-09-07

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 18

Registration Number: NCT00822848

Locations: 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

Assessing Dynamic Magnetic Resonance (MR) Imaging in Patients With Recurrent High Grade Glioma Receiving Chemotherapy

Phase 1

Terminated

Conditions: Brain Neoplasms

Interventions: Drug: Ferumoxytol

First Posted Date: 2008-10-08

Last Posted Date: 2017-04-21

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 6

Registration Number: NCT00769093

Locations: 🇺🇸
Oregon Health & Science University, Portland, Oregon, United States

Vorinostat, Cladribine, and Rituximab in Treating Patients With Mantle Cell Lymphoma, Relapsed Chronic Lymphocytic Leukemia, or Relapsed B Cell Non-Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Recurrent B-Cell Non-Hodgkin Lymphoma
Recurrent Indolent Adult Non-Hodgkin Lymphoma
Recurrent Chronic Lymphocytic Leukemia
Refractory B-Cell Non-Hodgkin Lymphoma

Interventions: Drug: Cladribine
Other: Laboratory Biomarker Analysis
Biological: Rituximab
Drug: Vorinostat

First Posted Date: 2008-10-02

Last Posted Date: 2017-12-11

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 57

Registration Number: NCT00764517

Locations: 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
🇺🇸
Penn State Milton S Hershey Medical Center, Hershey, Pennsylvania, United States

Radiolabeled Glass Beads Used for Treating Patients With Primary Liver Cancer When Surgery is Not an Option

Not Applicable

Completed

Conditions: Hepatoma
Liver Cancer

Interventions: Device: Yttrium 90 (TheraSphere)

First Posted Date: 2008-08-25

Last Posted Date: 2022-09-30

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 339

Registration Number: NCT00740753

Sorafenib and Fulvestrant in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Aromatase Inhibitor Therapy

Phase 2

Terminated

Conditions: Breast Cancer

Interventions: Drug: fulvestrant
Drug: sorafenib tosylate

First Posted Date: 2008-07-25

Last Posted Date: 2018-02-26

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 12

Registration Number: NCT00722072

Locations: 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

Neurotoxicity in Primary Central Nervous System Lymphoma (PCNSL): An International Observational Study of Cognition in Long Term Survivors

Terminated

Conditions: Primary Central Nervous System Lymphoma (PCNSL)

First Posted Date: 2008-07-04

Last Posted Date: 2017-04-21

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 80

Registration Number: NCT00710151

Locations: 🇩🇪
Charite University Medicine, Berlin, Germany
🇩🇪
University Medical Center, Freiburg, Germany
🇩🇪
University of Bochum, Bochum, Germany

and more 1 locations

Clofarabine and Rituximab in Treating Patients With Relapsed Non-Hodgkin Lymphoma

Phase 1

Terminated

Conditions: Lymphoma

Interventions: Biological: rituximab
Drug: clofarabine
Genetic: DNA methylation analysis
Genetic: gene expression analysis
Genetic: microarray analysis
Genetic: polymerase chain reaction
Other: high performance liquid chromatography
Other: laboratory biomarker analysis

First Posted Date: 2008-06-05

Last Posted Date: 2019-11-27

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 2

Registration Number: NCT00691652

Locations: 🇺🇸
Knight Cancer Institute at Oregon Health and Science University, Portland, Oregon, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy